{
  "docId": "019de075-ab2a-73e5-980a-7d480707ba09",
  "docSlug": "340a1966b9939070959283ec1665bfbf",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 49,
  "pageCount": 60,
  "prevPage": 48,
  "nextPage": 50,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "Data cut-off date May 1, 2023. DL1-3 completed, DL4 open.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-ab2a-73e5-980a-7d480707ba09/49",
  "deckHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09",
  "deckJsonHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09.json",
  "deckAnchorHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09#slide-49",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.43,
        "x": 0.53,
        "y": 0.15
      },
      "kind": "callout",
      "text": "First-in-class Opportunity to Address STAT3-driven Pathology Across Diverse Indications",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8993ba6d-6c7c-4a67-979c-5a3833058205",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.43,
        "x": 0.53,
        "y": 0.35
      },
      "kind": "list",
      "text": "First heterobifunctional degrader against an undrugged target in the clinic; Clinical development strategy includes monotherapy direct registrational path in STAT3 dependent T cell malignancies; Opportunity for expansion into solid tumors in combination with immune checkpoint inhibitors.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2041726a-dc68-4119-b1d5-3fb4959d7cdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.45,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "list",
      "text": "As of the data cut-off of May 1, 2023: PK and PD profiles in DL1-3* consistent with preclinical data; Proof-of-mechanism for KT-333 demonstrated with up to 88% mean max degradation of STAT3; This profile is nearing 90% target degradation; The most common adverse events were Grade 1 and 2; Expect to be at potentially clinically active exposures at DL4 and beyond.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb93011d-a774-492f-93cb-579c410d1983",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.04,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "*DL1-3 have been completed and DL4 remains open to accrual.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "929e085e-f944-4aa6-b067-f5ca14fe678b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.72,
        "x": 0.14,
        "y": 0.04
      },
      "kind": "title",
      "text": "Desired Translation of PK, PD and Safety of KT-333",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2eba2d36-f084-432d-b432-3b9a47027eb3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Big Idea Formula",
      "slug": "big-idea-formula",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "7863432f-f747-4a4f-86ce-dc8477dfca0e",
      "evidence": "The slide presents a clear and concise value proposition, highlighting KT-333's potential as a first-in-class opportunity.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 49,
      "from": 42,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "0814ecd6-3302-463c-8283-d9c36bf778b3",
      "evidence": "The deck presents the why, what, and how of STAT3 as a target",
      "position": 2,
      "objective": "Why is STAT3 a good target for oncology?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}